InvestmentPitch Media Video Discusses Love Pharma, a New Listing on the CSE, Focused on the Global Sexual Health, Wellness, and Psychedelics Markets - Video Available on Investmentpitch.com

Love Pharma Inc. (CSE: LUV) is one of the latest new listings on the Canadian Securities Exchange, trading under the symbol "LUV", having previously traded as Glenbriar Technologies, prior to its fundamental change of business. Founded in 2020, Love Pharma is focused on the Global Sexual Health, Wellness, and Psychedelics markets, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life.

For more information, please view the InvestmentPitch Media "video" which provides additional information about this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Love Pharma" in the search box.

Love Pharma acquired BC-based Kick Pharmaceuticals, a specialized health and wellness company with exclusive rights and licenses to produce, market, package, sell and distribute six pharmaceutical and therapeutic products throughout Europe, North America and the United Kingdom. Kick also holds the rights to a patent application for an alternate delivery system for the drug Nabilone, an FDA approved, medical grade synthetic cannabinoid.

Love Pharma issued 183,067,857 shares at a deemed value of $0.10 per share to the shareholders of Kick. In concurrent transactions, Love issued 23 million shares to two other parties, acquiring additional patents, intellectual property, and license agreements.

The company is initially launching Bloom, a topical gel that increases blood circulation and sensitivity, with future hemp-infused versions, designed to further improve blood circulation and sensitivity, along with Auralief, a discreet cannabis-infused oral strip that expedites and enhances the desired effects of THC and CBD. The company has a number of other proven products in the pipeline to aid in mental and sexual health and wellness.

The company is addressing several large and rapidly growing markets with the global sexual wellness market forecasted to reach to about US37.2 billion by 2023. Although the legal market for psychedelic products is still in its early stages, with the Global Psychedelic Drugs Market valued at US3.8 billion in 2020, it is forecasted to more than double to US$7.58 billion by 2026.

To address this market, Love Pharma and its partners are currently developing a biosynthetic psilocybin-infused oral strip using its existing intellectual property developed for the mucoadhesive CBD strip. The company is also actively seeking additional mergers and acquisitions to complement its strong portfolio of intellectual property.

The shares are trading at $0.14. For more information, please visit the company's website www.love-pharma.com, contact Zach Stadnyk, President and CEO, at 604-343-2977 or by email at investors@love-pharma.com.

About InvestmentPitch Media

InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company's story ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

InvestmentPitch Media
Barry Morgan, CFO

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/98220

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Pure Life Healthcare Management CEO Doug Page

"Wrap-around Care" Model Helps Address Gaps in Mental Healthcare

With over 1.3 million Canadians currently struggling with trauma and post-traumatic stress disorder (PTSD), Pure Life Healthcare Management is working to offer a wrap-around care model for better healing, according to CEO Doug Page.

The model allows individuals to walk in and have a single health provider deliver a wide spectrum of support for healing.

“What we’re trying to do is build out both from a telehealth perspective with physical locations where you’re able to walk in and get 20 different services … Some clients might only need two or three services. Some clients are going to be accessing that dozen-plus different services, depending on what their background is,” Page said.

Keep reading...Show less
pills spilling out of a pill bottle on a yellow background

Pharma Stocks: 5 Biggest Companies

The biggest pharmaceutical companies in the world are responsible for developing and manufacturing the vast majority of prescription drugs, giving them a key role in the life science industry.

The pharma sector is responsible for the discovery, development and manufacturing of drugs and medicine. Companies are developing innovative treatments in areas like immuno-oncology and neurology, as well as novel options for rare diseases. 2023 in particular has seen a lot of buzz around diabetes and weight loss treatments.

With the pharmaceutical sector projected to reach a staggering US$1.6 trillion in total revenue by 2028, the need for the industry is great. Opportunities for investment are also sizeable, but what's the best place to start? Those who want exposure to the pharma market may want to begin by looking at the major players in the space.

Keep reading...Show less
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today that study results demonstrated an experimental model of pericarditis induces mesothelial to mesenchymal transition ("MMT") and that this process is inhibited by cannabidiol treatment, the active pharmaceutical ingredient in CardiolRx™. An abstract summarizing these results was submitted by the Company's international research collaborators from the University of Virginia and Houston Methodist DeBakey Heart & Vascular Center to the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases ("MPD2023") held on November 15 and 16, 2023 in Belgrade, Serbia.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics

Cardiol Therapeutics

Keep reading...Show less

Jamieson Wellness Inc. Reports Strong Third Quarter 2023 Results

Consolidated revenue growth of 9.1%;
Jamieson Brands revenue grew 15.0% led by increased demand in the U.S. and China

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) today reported its third quarter results for the period ended September 30, 2023. All amounts are expressed in Canadian dollars.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Jamieson Wellness Inc. Announces Normal Course Issuer Bid

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) announced today that it has received approval from the Toronto Stock Exchange (the "TSX") to commence a normal course issuer bid (the "NCIB"). The Company may purchase for cancellation up to 4,165,201 common shares of the Company pursuant to the NCIB, which represents approximately 10% of the Company's public float (as that term is defined in the policies of the TSX) as of October 30, 2023. The NCIB will commence on November 7, 2023 and will expire on the earlier of November 6, 2024, or the date on which the Company has either acquired the maximum number of common shares allowable or otherwise decided not to make any further repurchases. As of October 30, 2023, there were 42,087,169 common shares issued and outstanding.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News